NYSE · CIK 0000725363
CVM CEL SCI CORP
Insider trading from SEC Form 4. Last filing 12 d ago. Close $1.94 on Oct 9, 2026, +100% from the 52-week low and -81% from the high.
CEL SCI CORP (CVM) has 43 SEC Form 4 filings on file from 6 insiders, the latest filed on Oct 1, 2026. In the last 90 days insiders made 1 open-market buy worth $138k and 0 open-market sells worth $0, net +$138k.
7 open-market trades have been scored at CVM. The newest: Geert R Kersten (Chief Executive Officer) bought $138k of stock on Aug 25, 2026, filed Aug 26, 2026, scored 50 (moderate). The largest of the 7 shown: Geert R Kersten (Chief Executive Officer) bought $360k on May 14, 2026, scored 73 (notable). 2 insiders bought within 14 days of each other around Jul 25, 2025.
CVM closed at $1.94 on Oct 9, 2026, 100% above its 52-week low and 81% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at CEL SCI CORP, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Geert R Kersten Chief Executive Officer buy | $138k 100,000 shares | +46% | +53% from low-89% from high | |
| 73Notable | Geert R Kersten Chief Executive Officer buy | $360k 300,000 shares | +2598% | +9% from low-90% from high | |
| 63Notable | Geert R Kersten Chief Executive Officer buy | $119k 100,000 shares | +82% | +1% from low-91% from high | |
| 56Moderate | Geert R Kersten Chief Executive Officer buy | $200k 38,023 shares | +46% | +205% from low-58% from high | |
| 35Weak | Geert R Kersten Chief Executive Officer buy | $50k 8,389 shares | +11% | - | |
| 33Weak | Robert Eugene Watson director buy | $20k 2,919 shares | +359% | - | |
| 55Moderate | Geert R Kersten Chief Executive Officer buy | $200k 29,197 shares | +67% | - |
Transactions
Every row filed, 43 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Patricia B Prichep Chief Financial Officer | AGrant or award Common Stock | +2,082 | $2.06 | $4,289 | 19,571 | 12 d ago |
| Sep 30, 2026 | Geert R Kersten Chief Executive Officer | AGrant or award Common Stock | +2,621 | $2.06 | $5,399 | 318,763 | 12 d ago |
| Sep 30, 2026 | Eyal Talor Chief Scientific Officer | AGrant or award Common Stock | +1,165 | $2.06 | $2,400 | 10,483 | 12 d ago |
| Aug 25, 2026 | Geert R Kersten Chief Executive Officer | POpen-market purchase Common Stock | +100,000 | $1.38 | $138k | 316,142 | Aug 26, 2026 |
| Aug 14, 2026 | Bruno Jean-Marie Baillavoine director | AGrant or award Optionsderivative | +110,000 | $0.01 | $1,100 | 138,021 | Aug 17, 2026 |
| Aug 14, 2026 | Geert R Kersten Chief Executive Officer | AGrant or award Optionsderivative | +300,000 | $0.01 | $3,000 | 452,380 | Aug 17, 2026 |
| Aug 14, 2026 | Patricia B Prichep Chief Financial Officer | AGrant or award Optionsderivative | +225,000 | $0.01 | $2,250 | 299,693 | Aug 17, 2026 |
| Aug 14, 2026 | Eyal Talor Chief Scientific Officer | AGrant or award Optionsderivative | +250,000 | $0.01 | $2,500 | 331,625 | Aug 17, 2026 |
| Aug 14, 2026 | John Cipriano Senior Vice President | AGrant or award Optionsderivative | +80,000 | $0.01 | $800 | 118,010 | Aug 17, 2026 |
| Aug 14, 2026 | Robert Eugene Watson director | AGrant or award Optionsderivative | +110,000 | $0.01 | $1,100 | 137,271 | Aug 17, 2026 |
| Jun 30, 2026 | Patricia B Prichep Chief Financial Officer | AGrant or award Common Stock | +4,125 | $1.04 | $4,290 | 17,489 | Jul 1, 2026 |
| Jun 30, 2026 | Eyal Talor Chief Scientific Officer | AGrant or award Common Stock | +2,307 | $1.04 | $2,399 | 9,318 | Jul 1, 2026 |
| Jun 30, 2026 | Geert R Kersten Chief Executive Officer | AGrant or award Common Stock | +5,192 | $1.04 | $5,400 | 216,142 | Jul 1, 2026 |
| May 14, 2026 | Geert R Kersten Chief Executive Officer | POpen-market purchase Common Stockindirect: Trustee | +300,000 | $1.20 | $360k | 311,547 | May 18, 2026 |
| May 13, 2026 | Geert R Kersten Chief Executive Officer | POpen-market purchase Common Stock | +100,000 | $1.19 | $119k | 222,497 | May 14, 2026 |
| Mar 31, 2026 | Geert R Kersten Chief Executive Officer | AGrant or award Common Stock | +1,682 | $3.21 | $5,399 | 122,497 | Apr 1, 2026 |
| Mar 31, 2026 | Patricia B Prichep Chief Financial Officer | AGrant or award Common Stock | +1,336 | $3.21 | $4,289 | 13,364 | Apr 1, 2026 |
| Mar 31, 2026 | Eyal Talor Chief Scientific Officer | AGrant or award Common Stock | +747 | $3.21 | $2,398 | 7,011 | Apr 1, 2026 |
| Jan 22, 2026 | Geert R Kersten Chief Executive Officer | POpen-market purchase Common Stock | +38,023 | $5.26 | $200k | 120,815 | Jan 26, 2026 |
| Dec 31, 2025 | Eyal Talor Chief Scientific Officer | AGrant or award Common Stock | +456 | $5.26 | $2,399 | 6,264 | Jan 5, 2026 |
| Dec 31, 2025 | Geert R Kersten Chief Executive Officer | AGrant or award Common Stock | +998 | $5.26 | $5,249 | 82,792 | Jan 5, 2026 |
| Dec 31, 2025 | Patricia B Prichep Chief Financial Officer | AGrant or award Common Stock | +815 | $5.26 | $4,287 | 12,028 | Jan 5, 2026 |
| Dec 4, 2025 | Geert R Kersten Chief Executive Officer | POpen-market purchase Common Stock | +8,389 | $5.96 | $50k | 81,794 | Dec 5, 2025 |
| Sep 30, 2025 | Geert R Kersten Chief Executive Officer | AGrant or award Common Stock | +570 | $9.20 | $5,244 | 73,405 | Oct 2, 2025 |
| Sep 30, 2025 | Patricia B Prichep Chief Financial Officer | AGrant or award Common Stock | +466 | $9.20 | $4,287 | 11,213 | Oct 2, 2025 |
| Sep 30, 2025 | Eyal Talor Chief Scientific Officer | AGrant or award Common Stock | +260 | $9.20 | $2,392 | 5,808 | Oct 2, 2025 |
| Jul 28, 2025 | Robert Eugene Watson director | AGrant or award Optionsderivative | +4,000 | $0.01 | $40 | 27,266 | Jul 29, 2025 |
| Jul 25, 2025 | Robert Eugene Watson director | POpen-market purchase Common Stock | +2,919 | $6.85 | $20k | 3,733 | Jul 29, 2025 |
| Jul 28, 2025 | John Cipriano Senior Vice President | AGrant or award Optionsderivative | +7,500 | $0.01 | $75 | 38,008 | Jul 29, 2025 |
| Jul 28, 2025 | Eyal Talor Chief Scientific Officer | AGrant or award Optionsderivative | +15,000 | $0.01 | $150 | 81,622 | Jul 29, 2025 |
| Jul 28, 2025 | Patricia B Prichep Chief Financial Officer | AGrant or award Optionsderivative | +12,000 | $0.01 | $120 | 75,127 | Jul 29, 2025 |
| Jul 28, 2025 | Geert R Kersten Chief Executive Officer | AGrant or award Optionsderivative | +25,000 | $0.01 | $250 | 175,157 | Jul 29, 2025 |
| Jul 28, 2025 | Bruno Jean-Marie Baillavoine director | AGrant or award Optionsderivative | +4,000 | $0.01 | $40 | 28,017 | Jul 29, 2025 |
| Jul 25, 2025 | Geert R Kersten Chief Executive Officer | POpen-market purchase Common Stock | +29,197 | $6.85 | $200k | 72,835 | Jul 28, 2025 |
| Jun 30, 2025 | Geert R Kersten Chief Executive Officer | AGrant or award Common Stock | +2,292 | $2.29 | $5,249 | 43,638 | Jul 1, 2025 |
| Jun 30, 2025 | Patricia B Prichep Chief Financial Officer | AGrant or award Common Stock | +1,873 | $2.29 | $4,289 | 10,747 | Jul 1, 2025 |
| Jun 30, 2025 | Eyal Talor Chief Scientific Officer | AGrant or award Common Stock | +1,048 | $2.29 | $2,400 | 5,548 | Jul 1, 2025 |
| Mar 31, 2025 | Geert R Kersten Chief Executive Officer | AGrant or award Common Stock | +22,786 | $0.23 | $5,250 | 1,240,378 | Apr 1, 2025 |
| Mar 31, 2025 | Patricia B Prichep Chief Financial Officer | AGrant or award Common Stock | +15,432 | $0.23 | $3,556 | 266,230 | Apr 1, 2025 |
| Mar 31, 2025 | Eyal Talor Chief Scientific Officer | AGrant or award Common Stock | +10,416 | $0.23 | $2,400 | 135,013 | Apr 1, 2025 |
| Dec 31, 2024 | Patricia B Prichep Chief Financial & Operations | AGrant or award Common Stock | +10,727 | $0.40 | $4,291 | 250,798 | Jan 2, 2025 |
| Dec 31, 2024 | Eyal Talor Chief Scientific Officer | AGrant or award Common Stock | +6,001 | $0.40 | $2,400 | 124,597 | Jan 2, 2025 |
| Dec 31, 2024 | Geert R Kersten CEO | AGrant or award Common Stock | +12,940 | $0.40 | $5,176 | 1,217,592 | Jan 2, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Bruno Jean-Marie Baillavoinedirector
- John CiprianoSenior Vice President
- Geert R KerstenChief Executive Officer
- Patricia B PrichepChief Financial Officer
- Eyal TalorChief Scientific Officer
- Robert Eugene Watsondirector
Questions about CVM
Answered from the filings on this page, as of the latest one.
Are insiders buying CVM?
As of Oct 1, 2026, SEC Form 4 filings show 1 open-market buy worth $138k by 1 insider and 0 open-market sells worth $0 by 0 insiders at CEL SCI CORP in the last 90 days, net +$138k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade CVM on the open market?
Geert R Kersten (Chief Executive Officer) bought $138k of CVM on Aug 25, 2026 and filed the Form 4 on Aug 26, 2026. InsiderTell scored 50 (moderate).
How many insiders file Form 4 at CEL SCI CORP?
6 people have filed a Form 4 at CEL SCI CORP, among them Bruno Jean-Marie Baillavoine (director), John Cipriano (Senior Vice President), Geert R Kersten (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.